Your browser doesn't support javascript.
loading
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy).
Ascierto, Paolo A; Blank, Christian; Dummer, Reinhard; Ernstoff, Marc S; Ferrone, Soldano; Fox, Bernard A; Gajewski, Thomas F; Garbe, Claus; Hwu, Patrick; Kalinski, Pawel; Krogsgaard, Michelle; Lo, Roger S; Luke, Jason J; Neyns, Bart; Postow, Michael A; Quezada, Sergio A; Teng, Michele W L; Trinchieri, Giorgio; Testori, Alessandro; Caracò, Corrado; Osman, Iman; Puzanov, Igor; Thurin, Magdalena.
Afiliación
  • Ascierto PA; Department of Melanoma, Cancer Immunotherapy and Innovative Therapy, Instituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy. paolo.ascierto@gmail.com.
  • Blank C; Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Dummer R; Department of Dermatology, University of Zurich Hospital, Zurich, Switzerland.
  • Ernstoff MS; Developmental Therapeutics Program, Division of Cancer Therapy & Diagnosis, NCI, NIH, Bethesda, MD, USA.
  • Ferrone S; Department of Surgery Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Fox BA; Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, OR, USA.
  • Gajewski TF; Department of Pathology and Department of Medicine (Section of Hematology/Oncology), University of Chicago, Chicago, IL, USA.
  • Garbe C; Center for Dermato-Oncology, University-Department of Dermatology, Tuebingen, Germany.
  • Hwu P; Moffitt Cancer Center, Tampa, FL, USA.
  • Kalinski P; Cancer Vaccine and Dendritic Cell Therapies, Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Developmental Therapeutics, Buffalo, NY, USA.
  • Krogsgaard M; Medical School, New York University Langone, New York, NY, USA.
  • Lo RS; Jonsson Comprehensive Cancer Center David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Luke JJ; Cancer Immunotherapeutic Center of UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
  • Neyns B; Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium.
  • Postow MA; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Quezada SA; Weill Cornell Medical College, New York, NY, USA.
  • Teng MWL; Cancer Immunology Unit, Research Department of Hematology, University College London Cancer Institute, London, UK.
  • Trinchieri G; QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
  • Testori A; Laboratory of Integrative Cancer Immunology (LICI), Center for Cancer Research, NCI, NIH, Bethesda, MD, USA.
  • Caracò C; Image Rigenerative Clinic-Skin Oncology Division, Milan, Italy.
  • Osman I; Chairman Surgical Subgroup EORTC Melanoma Group Brussels, Brussels, Belgium.
  • Puzanov I; Division of Surgery of Melanoma and Skin Cancer, Istituto Nazionale Tumori "Fondazione Pascale" IRCCS, Naples, Italy.
  • Thurin M; New York University Langone Medical Center, New York, NY, USA.
J Transl Med ; 19(1): 278, 2021 06 30.
Article en En | MEDLINE | ID: mdl-34193182
Advances in immune checkpoint therapy and targeted therapy have led to improvement in overall survival for patients with advanced melanoma. Single agent checkpoint PD-1 blockade and combination with BRAF/MEK targeted therapy demonstrated benefit in overall survival (OS). Superior response rates have been demonstrated with combined PD-1/CTLA-4 blockade, with a significant OS benefit compared with single-agent PD-1 blockade. Despite the progress in diagnosis of melanocytic lesions, correct classification of patients, selection of appropriate adjuvant and systemic therapies, and prediction of response to therapy remain real challenges in melanoma. Improved understanding of the tumor microenvironment, tumor immunity and response to therapy has prompted extensive translational and clinical research in melanoma. Development of novel biomarker platforms may help to improve diagnostics and predictive accuracy for selection of patients for specific treatment. There is a growing evidence that genomic and immune features of pre-treatment tumor biopsies may correlate with response in patients with melanoma and other cancers but they have yet to be fully characterized and implemented clinically. Overall, the progress in melanoma therapeutics and translational research will help to optimize treatment regimens to overcome resistance and develop robust biomarkers to guide clinical decision-making. During the Melanoma Bridge meeting (December 3rd-5th, 2020, Italy) we reviewed the currently approved systemic and local therapies for advanced melanoma and discussed novel biomarker strategies and advances in precision medicine.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inmunoterapia / Melanoma Tipo de estudio: Prognostic_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: J Transl Med Año: 2021 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inmunoterapia / Melanoma Tipo de estudio: Prognostic_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: J Transl Med Año: 2021 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido